Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada
Clinical Pharmacology & Therapeutics · 2026-05 · 119 (5) · 1172-1178
DOI: 10.1002/cpt.70120 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 05.11.2025. Verfasst von Cheryl Grandinetti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), …. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.
Abstract (Originalsprache)
As clinical trial design and conduct continue to evolve with innovative approaches, new technologies, and emerging data sources, regulatory frameworks are undergoing significant updates to align with these advancements. This article explores recent revisions to the International Council for Harmonization (ICH) Guideline for Good Clinical Practice (GCP) E6(R3) and the regulatory perspectives on adopting a risk‐proportionate approach to trial design and conduct. Drawing from insights shared at the FDA‐MHRA‐HC 2024 Joint GCP Symposium, this article highlights the key themes shaping the future of clinical trials, including quality‐by‐design (QbD), risk proportionality, and cross‐regulatory collaboration. Additionally, this article addresses the impact of the COVID‐19 pandemic in accelerating trial innovations, such as the use of decentralized trial elements and digital health technologies (DHTs), while also emphasizing the need for regulatory flexibility to accelerate their adoption. Regulatory agencies, such as the US‐FDA, MHRA‐UK, and Health Canada, have issued guidance to promote clinical trial flexibilities and proportionate, risk‐based approaches, ensuring the protection of participant rights, safety, and well‐being and overall reliability of trial results. These updates advocate for proportionate approaches to trial oversight, which allow for innovation while safeguarding the trial's critical to quality factors. As regulators continue to refine their practices and enhance collaboration, the integration of QbD and risk proportionality into clinical trials and cross‐regulatory collaboration will ultimately drive more efficient, participant‐centered trials and improve the global clinical research landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
- Standards and Compliance Function, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.
- Regulatory Operations and Enforcement Branch (ROEB), Health Canada (HC), Ottawa, Ontario, Canada.
ORCID-Profile: Cheryl Grandinetti, Elena Boley, Leigh Marcus, Jenn Sellers, Kassa Ayalew
Förderung
- Intramural FDA HHS
Zitieren
APA
Grandinetti, C., Budwal-Jagait, M., Abid, H., Gebbia, E., Boley, E., Williams, L., Fisher, A., Marcus, L., Muldowney, L., Sellers, J., Wakelin-Smith, J., & Ayalew, K. (2026). Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada. Clinical Pharmacology & Therapeutics, 119(5), 1172-1178. https://doi.org/10.1002/cpt.70120
Vancouver
Grandinetti C, Budwal-Jagait M, Abid H, Gebbia E, Boley E, Williams L, et al. Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada. Clinical Pharmacology & Therapeutics. 2026;119(5):1172-1178. doi:10.1002/cpt.70120
BibTeX
@article{Grandinetti2026,
author = {Grandinetti, Cheryl and Budwal-Jagait, Mandy and Abid, Hocine and Gebbia, Emily and Boley, Elena and Williams, LaKisha and Fisher, Andrew and Marcus, Leigh and Muldowney, Laurie and Sellers, Jenn and Wakelin-Smith, Jason and Ayalew, Kassa},
title = {Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {5},
pages = {1172--1178},
doi = {10.1002/cpt.70120}
}
EUVIMED